|1.||Zhang, Guang-Yi: 3 articles (11/2005 - 04/2003)|
|2.||Tian, Hui: 3 articles (11/2005 - 06/2003)|
|3.||Georgescu, Michaela: 2 articles (07/2012 - 02/2006)|
|4.||Pfaus, James G: 2 articles (07/2012 - 02/2006)|
|5.||Wilhelm, Ethel A: 2 articles (06/2009 - 06/2008)|
|6.||Nogueira, Cristina W: 2 articles (06/2009 - 06/2008)|
|7.||Mello, Carlos Fernando: 2 articles (06/2006 - 09/2003)|
|8.||Zhao, Yan: 2 articles (12/2005 - 11/2004)|
|9.||Wang, Hui-Ling: 2 articles (12/2005 - 11/2004)|
|10.||Xiang, Xiao-Hui: 2 articles (12/2005 - 11/2004)|
03/08/1994 - "While D-AP5 had no protective effects, 50 microM DNQX protected most of the radial dendrites from the ischemia-induced swelling, excepting those contacting the modiolar side of the IHCs. "
09/01/2003 - "The results illustrated that NAC preferably inhibited the MLK3 activation during the ischemia and the early reperfusion, whereas DNQX effectively attenuated the MLK3 activation of the late reperfusion. "
04/01/1992 - "Conversely, after a perfusion of 50 microM 6-7-dinitroquinoxaline-2,3-dione (DNQX) before ischemia, most dendrites were protected although those contacting the IHCs on their modiolar side frequently swelled. "
07/25/2003 - "On the seventh day after ischemia, the increases in the CAP threshold and the progressive IHC loss were significantly reduced in cochleae treated with DNQX, while MK-801 was ineffective. "
06/01/2003 - "Antioxidant NAC and AMPA/KA receptor antagonist DNQX inhibited JNK3 activation following global ischemia in rat hippocampus."
08/01/2001 - "SCP or DNQX were generally ineffective in reducing or eliminating TMPP-induced seizures."
05/01/1990 - "DNQX was not effective when given either ICV or systemically, although a 3.78 micrograms dose of DNQX given ICV markedly increased the variability in latency to seizure onset, suggesting a combination of pro- and anticonvulsant effects. "
05/01/1995 - "In addition, in 7 to 25-day-old rats, DNQX and NBQX decreased the severity of seizures due to a decrease in total incidence of the tonic component of tonic-clonic seizures compared to age-matched controls. "
02/18/2015 - "Local application of BMI in the entorhinal cortex did not induce seizure-like events (SLEs), but did generate periodic interictal spikes sensitive to the glutamatergic non-NMDA receptor antagonist DNQX. "
09/10/2004 - "The suppression of seizure-induced proliferation of granule cell precursors by DNQX may be achieved by the direct action of DNQX on AMPA/KA receptors on the granule cell precursors. "
08/06/1993 - "Treatment with KB-2796 or DNQX administered intraperitoneally at a dose of 10 mg/kg twice 30 min before ischemia and immediately after ischemia was effective in reducing the extent of atrophy in both the ipsilateral ischemic and non-ischemic regions. "
08/06/1993 - "These results suggest that brain atrophy on the ipsilateral ischemic side develops time-sequentially after transient focal ischemia and that ischemia affects not only the primary ischemic focus but also remote regions through transsynaptic connections, and that KB-2796 and DNQX have beneficial effects on atrophy in the chronic phase after ischemia."
|4.||Ganglion Cysts (Ganglion)
09/01/2012 - "It has been widely accepted that the DNQX-sensitive, OFF transient responses in retinal amacrine cells and ganglion cells are mediated exclusively by HBCs. "
10/22/2003 - "Finally, habituation of gill withdrawal requires activation of NMDA-type and AMPA-type postsynaptic receptors within the abdominal ganglion, because it is blocked by infusion of dl-2-amino-5-phosphonovaleric acid or 6,7-dinitroquinoxaline-2,3-dione. "
03/01/1994 - "In contrast, two non-NMDA receptor antagonists, NBQX (2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo-(F)-quinoxalinedione) and DNQX (6,7-dinitro-quinoxaline-2,3-dione), produced substantial reductions in the light-evoked responses (82%) and resting firing rates (87%) of all ganglion cell classes. "
05/19/1989 - "The non N-methyl-D-aspartate (NMDA) receptor antagonists dinitroquinoxaline-2,3-dione (DNQX) and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), both inhibit the visually driven response of sustained ganglion cells in the cat retina in vivo. "
08/15/1996 - "Neither the nicotine- nor muscarine-induced increases of ganglion cell [Ca2+]i were blocked by the glutamate receptor antagonists 6,7-dinitroquinoxaline-2,3-dione and aminophosphonopentanoic acid. "
|5.||Hypotension (Low Blood Pressure)
04/01/2002 - "Intracortical infusion of CPP also failed to affect significantly, whereas local infusion of DNQX inhibited the hypotension-enhanced release of DA dose-dependently. "
04/01/2002 - "Infusion into the VTA of neither a NMDA receptor antagonist (CPP), nor a non-NMDA antagonist (DNQX) affected the hypotension-induced increase of DA in the PFC. "
08/01/1997 - "In contrast, arterial baroreflex activation induced by transient hypotension following intravenous sodium nitroprusside increases levels of plasma norepinephrine which are inhibited with intrathecal AP-5, but not DNQX. "
12/10/1990 - "Intra-NTS injections of glutamate caused hypotension and bradycardia, which were potentiated by baclofen, and were not affected by either DNQX or MK-801 or by pretreatment with pertussis toxin. "
|1.||2,3- dioxo- 6- nitro- 7- sulfamoylbenzo(f)quinoxaline (NBQX)
|2.||KB 2796 (lomerizine)
|3.||FG 9041 (DNQX)
|6.||Cocaine (Cocaine HCl)
|8.||Dizocilpine Maleate (Dizocilpine)
|9.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|10.||6-Cyano-7-nitroquinoxaline-2,3-dione (6 Cyano 7 nitroquinoxaline 2,3 dione)